Krystal Biotech Inc (KRYS NASDAQ) stock market data APIs
$323.8325
0.11(0%)
as of August 7, 2026
Try our APIs with
free plan!
Krystal Biotech Inc Financial Data Overview
Price chart is built with
Anychart
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Prev. Close
323.8325
Open
327.8773
High
329.6495
Low
318.1714
52 wk Range
136.73-382.535
Market Cap
9 551 M
P/E Ratio
40.4881
Shares Outstanding
29 599 K
Revenue
440 M
EPS
1.79
Beta
0.536
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Krystal Biotech Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Krystal Biotech Inc data using free add-ons & libraries
Get Krystal Biotech Inc Fundamental Data
Krystal Biotech Inc Fundamental data includes:
- Net Revenue: 440 M
- EBITDA: 199 M
- Earnings Per Share: 7
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-03
- EPS/Forecast: 1.7
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Krystal Biotech Inc News
New
Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus
Krystal Biotech KRYS reported second-quarter 2026 earnings per share (EPS) of $1.79, which surpassed the Zacks Consensus Estimate of $1.70. The company recorded an EPS of $1.29 in the year-ago quarter...
Stocks Settle Sharply Higher as Middle East Tensions Ease
The S&P 500 Index ($SPX) (SPY) on Monday closed up +1.48%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +1.32%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +1.78%. September E-m...
Krystal Biotech Inc (KRYS) (Q2 2026) Earnings Call Highlights: VYJUVEK Sales Surge 24% as ...
This article first appeared on GuruFocus. Net Revenue: $119.2 million from global sales of VYJUVEK, a 24% increase from $96 million in Q2 2025. US Net Revenue: $91.6 million for the quarter. Cost of ...
Stocks Settle Sharply Higher as Middle East Tensions Ease
Bull on Wall Street by Alexander Naumann via Pixabay The S&P 500 Index ($SPX) (SPY) on Monday closed up +1.48%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +1.32%, and the Nasdaq 100...
Get Krystal Biotech Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
